SCHEMBL1090210

SCHEMBL1090210

CC(C)C[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15658 1.00
SCHEMBL1089695 1.00
SCHEMBL17766840 1.00 TSHR (0.47)
Methyl Alcohol SCHEMBL19457756 0.96
Isobutanol SCHEMBL144682 0.89 TSHR (0.60)
Alcohol SCHEMBL3796705 0.89 TSHR (0.47)
Butanol SCHEMBL1682662 0.89 TSHR (0.67)
SCHEMBL21541629 0.87 TSHR (0.37)
Bicarbonate SCHEMBL2768596 0.87 RNPEP (0.48)
Phosphoric Acid SCHEMBL18826044 0.84 LAP3 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119776301-A Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds 杭州文德阶生物科技有限公司 2025-04-08 CN claimed
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PSOMAGEN, INC. (US) 2022-08-23 US claimed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 US claimed
EP-3668494-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE Psomagen, Inc. (US) 2020-06-24 EP claimed
CN-111163761-A Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide 普梭梅根公司 2020-05-15 CN claimed
WO-2019036507-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE uBiome, Inc. (US) 2019-02-21 WO claimed
US-20190050525-A1 RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES PSOMAGEN, INC. 2019-02-14 US claimed
EP-4370517-B1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS Galderma Holding SA (CH) 2025-12-24 EP disclosed
CN-119776301-A Alcohol dehydrogenase, recombinant genetically engineered bacterium and application thereof in asymmetric reduction of potential chiral carbonyl compounds 杭州文德阶生物科技有限公司 2025-04-08 CN disclosed
US-20250042908-A1 SALTS FOR MTOR COMPOUNDS GALDERMA HOLDING S A (CH) 2025-02-06 US disclosed
US-20240294532-A1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS GALDERMA HOLDING S.A. (CH) 2024-09-05 US disclosed
US-20240216377-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION 2024-07-04 US disclosed
EP-4370517-A1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS Galderma Holding SA (CH) 2024-05-22 EP disclosed
EP-0978504-A1 Anti-ferroelectric liquid crystal compound MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2000-02-09 EP disclosed
EP-0974636-A1 Ferrielectric liquid crystal compound MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2000-01-26 EP disclosed
EP-0893422-A1 Optically active alcohol and process for the production thereof MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1999-01-27 EP disclosed
EP-0776326-A4 PYRROLINONE-BASED PEPTIDOMIMETICS UNIV PENNSYLVANIA (US) 1998-05-06 EP disclosed
EP-0776326-A1 PYRROLINONE-BASED PEPTIDOMIMETICS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1997-06-04 EP disclosed
EP-0398288-B1 Process for preparing optically active 2-arylalkanoic acids, in particular 2-arylpropionic acids PUETTER MEDICE CHEM PHARM (DE) 1995-10-18 EP disclosed
US-5266723-A Process for the preparation of optically active 2-aryl-alkanoic acids, especially 2-aryl-propionic acids MEDICE, LTD., CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) 1993-11-30 US disclosed